Prurigo nodularis
MONDO:0026045Prurigonodularis (PN) is a skin disease in which hard crusty lumps are formed on the skin that itches intensely. Repetitive rubbing, scratching, and touching results in more lesions in the skin. The itching is so intense that people scratch themselves to the point of bleeding or pain. The lumps formed in the skin are hard, and have about a half inch across, with a dry and rough top that is often scratched open. They tend to be located in the areas most easily reached and are worse on the outer sides: arms, shoulders and legs. The trunk, face and even palms can also be affected. The exact cause is unknown but some factors triggering PN include liver and kidneys problems, nervous and mental conditions and other skin diseases. Prurigo nodulares, in some cases, can be seen in other diseases such as lymphoma, chronic autoimmune cholestatic hepatitis, HIV infection, severe anemia,or a chronic kidney disease-related itching known as uremic pruritus. Treatment is very difficult, and may include corticoids, antihistaminic and other medication such as thalidomide and similar (Lenalidomide). In some cases, cryotherapy, photochemotherapy and habit reversal therapy for the itch-scratch cycle has improved the symptoms. PN can last for many years, and the itching is so intense that may affect all the everyday activities.
29 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
New drug BGB-45035 tested for eczema and itchy skin condition
Disease control CompletedThis study tested a new drug called BGB-45035 for the first time in humans. It looked at safety in healthy volunteers and then in people with autoimmune skin diseases like atopic dermatitis (eczema) and prurigo nodularis (a condition causing intensely itchy bumps). The goal was t…
Phase: PHASE1 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for eczema sufferers with painful itchy nodules?
Disease control CompletedThis study tested the drug upadacitinib in people with moderate to severe atopic dermatitis (eczema) who also have prurigo nodularis, a condition causing intense itching and hard bumps. The goal was to see if the drug reduces itching and improves skin. The study was observational…
Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New shot could tame uncontrollable itch of prurigo nodularis
Disease control CompletedThis study tested the drug dupilumab in 151 adults with prurigo nodularis, a condition causing intense itching and raised skin bumps. Participants had severe itch that creams could not control. They received either dupilumab injections or a placebo for 24 weeks. The main goal was…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 26, 2026 18:24 UTC
-
New hope for chronic itch: dupilumab tackles prurigo nodularis
Disease control CompletedThis study tested the drug dupilumab in 160 adults with prurigo nodularis, a skin condition causing intense itching and bumps. Participants received either dupilumab injections or a placebo for up to 24 weeks. The main goal was to see if dupilumab could reduce itch by at least 4 …
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 26, 2026 17:54 UTC
-
New injection shows promise for relieving intense itching
Symptom relief CompletedThis Phase 3 trial tests whether Stapokibart injection can reduce severe itching and skin bumps in adults with prurigo nodularis. About 200 participants will receive either the drug or a placebo for 24 weeks. The main goal is to see if itching improves by at least 4 points on a 0…
Phase: PHASE3 • Sponsor: Keymed Biosciences Co.Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
New drug KPL-716 aims to stop the itch of prurigo nodularis
Symptom relief CompletedThis phase 2 trial tested an investigational drug called KPL-716 (vixarelimab) in 240 adults with prurigo nodularis, a skin condition causing intense itching and hard nodules. The study compared the drug to a placebo to see if it could reduce itch severity over several weeks. The…
Phase: PHASE2 • Sponsor: Genentech, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 08:10 UTC
-
Itch-Busting cream shows promise for painful skin bumps
Symptom relief CompletedThis Phase 3 trial tested a cream called ruxolitinib (also known as Opzelura) in 190 adults with prurigo nodularis, a skin condition causing intense itching and hard bumps. Participants applied the cream twice daily for 12 weeks. The main goal was to see if it could reduce itch b…
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Symptom relief
Last updated Jun 27, 2026 08:05 UTC
-
Eye movement therapy shows promise for itchy skin conditions
Symptom relief CompletedThis study tested a behavioral therapy called EMD-U in 96 adults with atopic dermatitis or prurigo nodularis who had a strong urge to scratch. The therapy involves focusing on the itchy spot while moving the eyes, repeated until the urge fades. Researchers compared EMD-U plus usu…
Phase: NA • Sponsor: Tamar Nijsten • Aim: Symptom relief
Last updated Jun 27, 2026 07:59 UTC
-
New cream offers hope for unbearable itch
Symptom relief CompletedThis Phase 3 trial tested a cream containing ruxolitinib in 204 adults with prurigo nodularis, a skin condition causing intense itching and hard bumps. Participants applied the cream twice daily for 12 weeks. The main goal was to see if it reduced itch by at least 4 points on a 0…
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Symptom relief
Last updated Jun 27, 2026 07:57 UTC
-
AI could cut skin specialist wait times, study hints
Knowledge-focused CompletedThis study tested an artificial intelligence algorithm designed to help primary care doctors decide whether a patient with a skin condition really needs to see a dermatologist. Researchers enrolled 200 adults with skin problems and had their doctors take photos of the affected ar…
Sponsor: AI Labs Group S.L • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC